PDCD1 and Thrombocytopenia: The results of our study demonstrate that early recognition of PD-1 inhibitor–induced thrombocytopenia, coupled with prompt and precise interventions, can lead to favorable outcomes even in patients with advanced malignancies and bone metastasis.